Cargando…
First report of the unique expression of RECAF (receptor for alfa feto-protein) in adult B-NHL/CLL patients
BACKGROUND: Lymphoproliferative disorders (LPDs) are a heterogeneous group of diseases characterized by an uncontrolled production of monoclonal lymphocytes. RECAF is the receptor for alpha-fetoprotein, which is re-expressed on malignant cells, thus serving as a broad-spectrum tumor marker. METHODS:...
Autores principales: | Sedky, Hebatallah Adel, Youssef, Soha Raouf, Gamal, Doaa Ahmad, Houssein, Heba Fawzy, Elsalakawy, Walaa Ali |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7784125/ https://www.ncbi.nlm.nih.gov/pubmed/33303704 http://dx.doi.org/10.5045/br.2020.2020070 |
Ejemplares similares
-
PI3k Inhibitors in NHL and CLL: An Unfulfilled Promise
por: Bou Zeid, Naji, et al.
Publicado: (2023) -
Combination of CA125 and RECAF biomarkers for early detection of ovarian cancer
por: Tcherkassova, Janneta, et al.
Publicado: (2011) -
First report of expansion of CD4(+)/CD28 null T-helper lymphocytes in adult patients with idiopathic autoimmune hemolytic anemia
por: Youssef, Soha R., et al.
Publicado: (2021) -
Idelalisib: The First-in-Class Phosphatidylinositol 3-Kinase Inhibitor for Relapsed CLL, SLL, and Indolent NHL
por: Forcello, Nicholas, et al.
Publicado: (2014) -
First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL
por: Byrd, John C., et al.
Publicado: (2018)